Myelo-ablative chemo/radiotherapy and autologous stem cell transplantation as compared to only chemotherapy in patients with multiple myeloma

ISRCTN ISRCTN82155239
DOI https://doi.org/10.1186/ISRCTN82155239
Secondary identifying numbers Ho24
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
09/11/2007
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr H.M. Lokhorst
Scientific

University Medical Center Utrecht
Department of Hematology
P.O. Box 85500
Utrecht
3508 GA
Netherlands

Phone +31 (0)30 2507230
Email h.lokhorst@digd.azu.nl

Study information

Study designMulticentre, randomised, active controlled, parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymHOVON 24 MM
Study objectivesThe hypothesis to be tested is that the outcome in arm II (and Allogeneic Bone Marrow Transplant [ABMT]) is better than in arm I.

Objectives:
1. Evaluation of the effect of myeloablative chemo-/radiotherapy and autologous stem cell transplantation in comparison with chemotherapy alone with respect to the mentioned endpoints
2. Assessment of the value of risk factors at diagnosis with dose intensity of treatment
Ethics approval(s)Ethics approval received from the local medical ethics committee
Health condition(s) or problem(s) studiedMultiple Myeloma
InterventionPatients will be treated with 3 x VAD (vincristine, doxorubicine, dexamethasone). Patients less than or equal to 55 years with a Human Leukocyte Antigen (HLA) identical sibling will proceed to Allo BMT. All other eligible patients will be randomised between:
1. Arm I: PBSC pheresis after cyclophosphamide priming (cyclophosphamide, mesnum, G-CSF), IDM (melphalan, G-CSF) every 8 weeks 2 courses. In case of PR/CR maintenance therapy with IFN-alpha-2a until relapse. PBSCT may be performed after reinduction or relapse
2. Arm II: PBSC pheresis after cyclophosphamide priming (cyclophosphamide, mesnum, G-CSF), IDM (melphalan, G-CSF) q 8 weeks 2 courses. In case of PR/CR intensive treatment with cyclophosphamide/TBI and autologous transplantation, maintenance with IFN-alpha-2a until relapse
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Vincristine, doxorubicine, dexamethasone (VAD), cyclophosphamide, mesnum, Granulocyte Colony Stimulating Factor (G-CSF), melphalan
Primary outcome measureRemission rate.
Secondary outcome measures1. Event-free survival
2. Overall survival
3. Quality of life
4. Cost-benefit
Overall study start date07/11/1995
Completion date01/04/2000

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants452
Key inclusion criteriaAt entry:
1. Previously untreated multiple myeloma, stage 2 or 3 according to Salmon and Durie
2. Aged less than 66 years
3. World Health Organization (WHO) performance status 0 - 3
4. Informed consent

For Interferon (IFN) maintenance and Peripheral Blood Stem Cell Transplant (PBSCT) or Allogeneic Bone Marrow Transplant (ABMT):
1. At least Partial Remission (PR) after induction therapy
2. WHO performance status 0 - 2
3. Suitable peripheral stem or bone marrow graft
4. No active infections
5. Absence of severe cardiac, pulmonary, neurologic, psychiatric disease
6. Serum creatinine, bilirubin and transaminases of less than 2.5 x upper limit of normal values
7. Platelet count greater than 50 x 10^9/l
8. Absolute neutrophil count greater than 1 x 10^9/l
9. Informed consent
Key exclusion criteriaAt entry:
1. Received more than 2 courses of melphalan, prednisone or vincristine, melphalan (M), cyclophosphamide, prednisone (VMCP)
2. Severe cardiac disease (= severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45% with presence of normal hemoglobin), severe pulmonary, neurologic or metabolic disease- Inadequate liver function, i.e., bilirubin greater than or equal to 25 x upper normal value
3. Prior malignancies except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma
4. Prior extensive radiotherapy involving the myelum (precluding total body irradiation)
Date of first enrolment07/11/1995
Date of final enrolment01/04/2000

Locations

Countries of recruitment

  • Netherlands

Study participating centre

University Medical Center Utrecht,
Utrecht
3508 GA
Netherlands

Sponsor information

Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)
Research organisation

Vrije University Medical Centre (VUMC)
PO Box 7057
Amsterdam
1007 MB
Netherlands

Phone +31 (0)20 444 2693
Email hdc@hovon.nl
Website http://www.hovon.nl/
ROR logo "ROR" https://ror.org/056kpdx27

Funders

Funder type

Industry

Roche Nederland B.V. (The Netherlands)

No information available

Amgen (The Netherlands)
Government organisation / For-profit companies (industry)
Alternative name(s)
Amgen Inc., Applied Molecular Genetics Inc.
Location
United States of America
Johnson & Johnson (The Netherlands)
Government organisation / For-profit companies (industry)
Alternative name(s)
Johnson & Johnson, johnson & Johnson Services, Inc., Johnson&Johnson, 强生公司, Johnson & Johnson Private Limited, ジョンソン・エンド・ジョンソント, J&J, JNJ
Location
United States of America
Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)

No information available

Novartis Pharma B.V. (The Netherlands)

No information available

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Other publications 15/03/2003 Yes No
Results article 01/05/2003 Yes No
Other publications 01/05/2004 Yes No